A biologic treatment for adult patients living with moderate to severe Plaque Psoriasis, adults with active Psoriatic Arthritis, adults with moderate to severe active Crohn's Disease, and adults with moderate to severe Ulcerative Colitis. See SKYRIZI®
SKINVIVE™ by JUVÉDERM® Share Link click to copy Information Directions for Use Patient Labeling Consumer Website HCP Website JUVEDERM® and its design are trademarks of Allergan Holdings France SAS, an AbbVie company. SKYRIZI® risankizumab-rzaa Share Link click to copy Information...
This includes a total of six additional indications for RINVOQ and SKYRIZI, expanded indications for VENCLEXTA, and several other near-term product — new product approvals including atogepant, Navitoclax and ABBV-951. Clearly, this is a very exciting time for AbbVie, and I’m pleased with ...
AbbVie also submitted regulatory applications for an additional indication for Skyrizi for the treatment of patients 16 years and older with moderate to severe Crohn’s Disease (CD), as well as Rinvoq in two additional indications: for the treatment of adults with moderately to severely active ...